Videos
Expert Perspectives: Rationale for CDK 4/6 Inhibition in Breast Cancer
02/21/2018
The cyclin-dependent kinase (CDK) pathway is critical to cell cycle entry. In many tumor types, including breast cancer, there is dysregulation of this pathway. This activity describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive (ER+) metastatic breast cancer using selective CDK 4/6 inhibitors.
This content was originally published on Imedex.
